Press Releases

News Brief

Samsung Biologics hosts Annual General Meeting of Shareholders


Samsung Biologics hosts Annual General Meeting of Shareholders

 

Samsung Biologics hosted its 14th Annual General Meeting of Shareholders.


The shareholders approved all agenda items as proposed, including financial statements as well as appointments of internal and external board directors and an audit committee member.


“We thank our shareholders for continued trust and confidence in the company,” said John Rim, CEO and President of Samsung Biologics. “We will open a new era of growth with Bio Campus II and further build on our capabilities to deliver our full potential, maximizing client and stakeholder satisfaction.”


Samsung Biologics expects to maintain positive growth momentum this year through quality and operational excellence. The company also continues to invest in capacity, portfolio, and geographical expansion.


Plant 5, the first facility of Bio Campus II, will be operational next month, adding fresh capacity of 180,000 liters. Samsung Biologics has also launched ADC services at its dedicated, standalone facility. Earlier this year, the company opened a sales office in Tokyo to better support clients in Japan and the wider APAC region.


Detailed information on the Annual General Meeting is available here.


Samsung Biologics hosts Annual General Meeting of Shareholders

 

Samsung Biologics hosted its 14th Annual General Meeting of Shareholders.


The shareholders approved all agenda items as proposed, including financial statements as well as appointments of internal and external board directors and an audit committee member.


“We thank our shareholders for continued trust and confidence in the company,” said John Rim, CEO and President of Samsung Biologics. “We will open a new era of growth with Bio Campus II and further build on our capabilities to deliver our full potential, maximizing client and stakeholder satisfaction.”


Samsung Biologics expects to maintain positive growth momentum this year through quality and operational excellence. The company also continues to invest in capacity, portfolio, and geographical expansion.


Plant 5, the first facility of Bio Campus II, will be operational next month, adding fresh capacity of 180,000 liters. Samsung Biologics has also launched ADC services at its dedicated, standalone facility. Earlier this year, the company opened a sales office in Tokyo to better support clients in Japan and the wider APAC region.


Detailed information on the Annual General Meeting is available here.

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Interests
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy required
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION